SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Olsen Michael Hecht)
 

Search: WFRF:(Olsen Michael Hecht) > Effects of losartan...

  • Olsen, Michael HechtGlostrup University Hospital, Glostrup, Denmark (author)

Effects of losartan compared with atenolol on lipids in patients with hypertension and left ventricular hypertrophy : the losartan intervention for endpoint reduction in hypertension (LIFE) study

  • Article/chapterEnglish2009

Publisher, publication year, extent ...

  • 2009
  • printrdacarrier

Numbers

  • LIBRIS-ID:oai:DiVA.org:umu-38999
  • https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-38999URI
  • https://doi.org/10.1097/HJH.0b013e32831daf96DOI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:118618634URI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • Objective: Beta-blockers and angiotensin II receptor blockers have different effects on lipids. Methods: We examined lipid levels in the Losartan Intervention For Endpoint reduction in hypertension study and their impact on the primary composite endpoint of cardiovascular death, myocardial infarction, or stroke. We measured total and high-density lipoprotein cholesterol at baseline and annually during 4.8 years of losartan-based compared with atenolol-based treatment in 8611 patients with hypertension and left ventricular hypertrophy. Results: Patients randomized to losartan-based or atenolol-based treatment had similar baseline total (6.04 ± 1.12 vs. 6.05 ± 1.13 mmol/l, NS) and high-density lipoprotein (HDL) cholesterol (1.50 ± 0.44 vs. 1.49 ± 0.44 mmol/l, NS). Total cholesterol decreased significantly but equally (-0.37 ± 1.05 vs. -0.34 ± 1.09 mmol/l, NS), whereas HDL cholesterol decreased less during the first 2 years in patients randomized to losartan compared with atenolol (-0.13 ± 0.24 vs. -0.19 ± 0.25 mmol/l) and remained higher each year (1.38, 1.37, 1.42, 1.47, and 1.48 mmol/l vs. 1.32, 1.30, 1.36, 1.40, and 1.42 mmol/l, all P < 0.001) independent of hydrochlorothiazide or statin treatment. In Cox regression analysis, baseline total cholesterol [hazard ratio (HR) = 1.08 (1.02–1.14) per mmol/l, P < 0.01], HDL cholesterol [HR = 0.56 (0.48–0.66) per mmol/l, P < 0.001], and treatment allocation [HR = 0.86 (0.76–0.98), P < 0.05] predicted composite endpoint independently. Using time-varying analyses, the predictive strength of HDL cholesterol was increased [HR = 0.36 (0.30–0.44) per mmol/l, P < 0.001], whereas that of total cholesterol [HR = 1.03 (0.97–1.09) per mmol/l, NS] and treatment allocation [HR = 0.91 (0.80–1.03), NS] were reduced. Conclusion: Losartan blunted the decrease in HDL cholesterol during antihypertensive treatment in the LIFE study. Higher intreatment HDL cholesterol was associated with fewer composite endpoints and may partly explain the better outcome of losartan-based treatment.

Added entries (persons, corporate bodies, meetings, titles ...)

  • Wachtell, KristianRigshospitalet, Copenhagen, Denmark (author)
  • Beevers, GarethCity Hospital, Birmingham, UK (author)
  • Dahlöf, BjörnSahlgrenska University Hospital/Östra, Göteborg, Sweden (author)
  • de Simone, GiovanniFederico II University of Naples, Naples, Italy (author)
  • Devereux, Richard BWeill Cornell Medical College, New York City, New York, USA (author)
  • de Faire, UlfKarolinska Institutet (author)
  • Fyhrquist, FrejHelsinki University Central Hospital, Helsinki, Finland (author)
  • Ibsen, HansGlostrup University Hospital, Glostrup, Denmark (author)
  • Kjeldsen, Sverre EUllevaal University Hospital, Oslo, Norway (author)
  • Lederballe-Pedersen, OleViborg Hospital, Viborg, Denmark (author)
  • Lindholm, Lars HUmeå universitet,Allmänmedicin(Swepub:umu)lali0003 (author)
  • Lyle, Paulette AMerck Research Laboratories, North Wales, Pennsylvania, USA (author)
  • Nieminen, Markku SHelsinki University Central Hospital, Helsinki, Finland (author)
  • Omvik, PerHaukeland University Hospital, Bergen, Norway (author)
  • Oparil, SuzanneUniversity of Alabama, Birmingham, Alabama, USA (author)
  • Wedel, HansNordic School of Public Health, Gothenburg, Sweden (author)
  • Glostrup University Hospital, Glostrup, DenmarkRigshospitalet, Copenhagen, Denmark (creator_code:org_t)

Related titles

  • In:Journal of Hypertension27:3, s. 567-5740263-63521473-5598

Internet link

Find in a library

To the university's database

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view